Ascendis Pharma A (ASND) EBT (2014 - 2026)
Ascendis Pharma A (ASND) posted EBT of -$56.4 million for Q1 2026, down 81.44% sequentially from -$31.1 million in Q4 2025, and up 42.69% YoY from -$39.5 million in Q1 2025.
Ascendis Pharma A (ASND) EBT (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported EBT for 13 years, with the latest figure at -$56.4 million in Q1 2026.
- Quarterly EBT rose 42.69% year-over-year to -$56.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$194.2 million (up 46.61% YoY) and the FY2025 annual result came in at -$247.5 million, up 37.94% from the prior year.
- EBT fell to -$56.4 million in Q1 2026 per ASND's latest filing, from -$31.1 million in the prior quarter.
- Over five years, EBT peaked at -$31.1 million in Q4 2025 and troughed at -$206.2 million in Q4 2022.
- A 5-year average of -$106.9 million and a median of -$107.8 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2025: EBT sank 85.04% in 2022, then soared 66.29% in 2025.
- Over 5 years, EBT stood at -$206.2 million in 2022, then soared by 57.68% to -$87.2 million in 2023, then surged by 54.21% to -$39.9 million in 2024, then increased by 22.19% to -$31.1 million in 2025, then plunged by 81.44% to -$56.4 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$56.4 million, -$31.1 million, and -$67.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.40 Mn |
| Dec 31, 2025 | -31.09 Mn |
| Sep 30, 2025 | -67.07 Mn |
| Jun 30, 2025 | -39.63 Mn |
| Mar 31, 2025 | -98.42 Mn |
| Dec 31, 2024 | -39.95 Mn |
| Sep 30, 2024 | -107.82 Mn |
| Jun 30, 2024 | -117.54 Mn |
| Mar 31, 2024 | -139.63 Mn |
| Dec 31, 2023 | -87.24 Mn |
| Sep 30, 2023 | -175.89 Mn |
| Jun 30, 2023 | -132.70 Mn |
| Mar 31, 2023 | -117.66 Mn |
| Dec 31, 2022 | -206.16 Mn |
| Sep 30, 2022 | -172.58 Mn |
| Jun 30, 2022 | -86.82 Mn |
| Mar 31, 2022 | -140.58 Mn |
| Dec 31, 2021 | -121.46 Mn |
| Sep 30, 2021 | -94.75 Mn |
| Jun 30, 2021 | -161.90 Mn |